Related Experiment Video
Updated: Jun 5, 2026
10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Hepatitis C in haematological patients
1Division of Haematology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
Hepatitis Research and Treatment
|December 29, 2010
Summary
Managing chronic hepatitis C during chemotherapy requires careful monitoring due to potential viral load increases and immune rebound. Antiviral treatment is typically delayed until after chemotherapy completion and immune recovery.
Area of Science:
- Hepatology
- Oncology
- Immunology
Background:
- No consensus exists for managing chronic hepatitis C in patients undergoing chemotherapy and immunosuppression.
- Literature suggests hepatitis C viral load may increase during chemotherapy.
- Risk of immune rebound and liver injury exists post-immunosuppression.
Purpose of the Study:
- To review current understanding and suggest prudent management strategies for chronic hepatitis C patients during chemotherapy.
- To highlight the importance of monitoring liver function in this patient population.
- To outline recommendations for initiating antiviral therapy.
Main Methods:
- Literature review of studies on hepatitis C management during chemotherapy and immunosuppression.
- Analysis of risks associated with viral load changes and immune rebound.
- Discussion of standard antiviral therapies.
Main Results:
- Close monitoring of liver function is crucial during chemotherapy for hematological malignancy.
- Antiviral treatment is generally deferred until chemotherapy completion and immune recovery to minimize toxicity.
- Pegylated interferon and ribavirin combination is the standard therapy for hepatitis C in hematological patients.
Conclusions:
- Careful management and monitoring are essential for chronic hepatitis C patients undergoing chemotherapy.
- Delayed antiviral treatment optimizes safety and efficacy.
- Standard therapy involves pegylated interferon and ribavirin post-chemotherapy.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:27Cytomegalovirus Disease
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
01:28Esophageal Varices-II: Clinical Features and Management
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...